SAN DIEGO, September 24, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of ...
Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) validated its Marketing Authorization Application for Diazoxide Choline ...
(RTTNews) - Aardvark Therapeutics, Inc. (AARD) announced Tuesday its participation in the 2025 United in Hope Conference for Prader-Willi syndrome or PWS on June 24-28 in Phoenix, Arizona. The company ...
Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe ...
Wells Fargo believes Acadia Pharmaceuticals’ (ACAD) Phase 3 failure removes a near-term competitor to Soleno Therapeutics’ (SLNO) VYKAT XR. Wells thinks Soleno’s shares should trade up at least 20% on ...
Investing.com - Wells Fargo has reiterated an Overweight rating and $123.00 price target on Soleno Therapeutics Inc. (NASDAQ:SLNO) following a competitor’s clinical trial failure. The Wells Fargo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback